The US Food and Drug Administration (FDA) has voluntarily recalled 101 products made by Strauss Israel for potential contamination with Salmonella.
Elite chocolate, cakes, chewing gum, energy chocolate rice cakes, energy grain snacks, and wafers are among the products recalled by Strauss.
The Elite items were distributed to stores in California, Connecticut, Florida, New Jersey, and New York. Amazon, Fresh Direct, Passover.com, and other online stores have also carried kosher chocolates. The FDA's website has a complete list of the products that have been recalled.
The impacted chocolates and candies were created in a facility where Salmonella was discovered in both the liquid chocolate used in the goods and on production line equipment, according to the FDA. Customers who have purchased the products can return them for a full refund, and any merchant who carries them has been requested to remove them from the sale. In addition to the 101 products recalled in the US, the Canadian Food Inspection Agency (CIFA) has discovered 97 potentially contaminated products on the Canadian market.
According to the Strauss Group, they decided to act fully responsibly, not to take any risks, and remove all the factory products from the shelves.
The company also apologized to the Israeli public, customers, and retailers for the difficulty, while thanking them for their patience and vow9ng to get back to all inquiries.
The recall was initially limited to "more than a dozen types of chocolate and chocolate used as raw ingredients," but it was later expanded to include Elite-brand items. Two out of 270 chocolate goods tested positive for salmonella when Strauss tested samples from its plant. Since then, manufacturing at the company's plant has been temporarily halted.
According to the FDA, no illnesses have been linked to the recall in the United States. In Israel, 21 people who consumed the contaminated products developed symptoms that were compatible with salmonella, and the country's Health Ministry took samples from them.


Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment
Indian Rupee Strengthens Sharply After U.S.-India Trade Deal Announcement
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
IMF Forecasts Global Inflation Decline as Growth Remains Resilient
Tesla Launches New Model Y Variant in the US Starting at $41,990
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
JPMorgan Lifts Gold Price Forecast to $6,300 by End-2026 on Strong Central Bank and Investor Demand
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 



